⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
Executive From Wegmans Food Markets Joins GS1 US Board of Governors
prnewswire.com
BJS
KSS
AMZN
KO
JNJ
K
PEP
PG
PSB
PVH
SYY
TGT
WMT
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
prnewswire.com
JNJ
DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
prnewswire.com
JNJ
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
prnewswire.com
JNJ
Johnson & Johnson to Participate in the Citi’s 2025 Global Healthcare Conference
businesswire.com
JNJ
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
prnewswire.com
IOVA
MRK
LLY
JNJ
Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
prnewswire.com
JNJ
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
prnewswire.com
JNJ
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
prnewswire.com
JNJ
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
prnewswire.com
JNJ